Lignocaine hydrochloride 1

All pre and post procedures were carried out as previously described^{52 (link)}. Briefly, eight New Zealand White rabbits were used for this study. All CE-CI procedures were performed by JSM. The use of rabbits, their care and treatment adhered to the regulation of the ARVO statement for the Use of Animals in Ophthalmic and Vision Research, and all experimental procedures were approved by the Institutional Animal Care and Use Committee of SingHealth, Singapore (Ref:2017/SHS/1292). All surgical procedures and follow-up evaluations were performed under general anesthesia achieved by intramuscular injections of 5 mg/kg xylazine hydrochloride (Troy Laboratories, New South Wales, Australia) and 50 mg/kg ketamine hydrochloride (Parnell Laboratories, New South Wales, Australia), along with topical application of lignocaine hydrochloride 1% (Pfizer Laboratories, New York, USA).

New Zealand white rabbits (n = 12) used in this study were separated into a treatment group of rabbits receiving SNEC injection (n = 4), a positive control group of rabbits receiving regular cultured CE-CI (n = 4), and a negative control group of rabbits receiving an injection of solution containing Y-27632 without CECs (n = 4). Lens extraction surgeries were performed by H.S.O. and F.M.-W., and cell-injection procedures were performed by J.S.M., V.K., and H.S.O. All surgical procedures and follow-up evaluations were performed under general anesthesia achieved by intramuscular injections of 5 mg/kg xylazine hydrochloride (Troy Laboratories, New South Wales, Australia) and 50 mg/kg ketamine hydrochloride (Parnell Laboratories, New South Wales, Australia), along with topical application of lignocaine hydrochloride 1% (Pfizer Laboratories, New York, NY, USA).